Sub menu

Vaccines

Comirnaty LP.8.1 5 years to <12 years (light blue cap) formulation

Details for Comirnaty LP.8.1 5 years to <12 years (light blue cap) formulation vaccine and its components.

Recently added

This page was added on 14 November 2024.

Updates made

This page was updated on [date-counter-updated-date]. View history of updates

Sponsor
Pfizer Australia
Administration route
Intramuscular injection
Vaccine group
Paediatric formulations
Description:

Registered for use in people aged 5 years to <12 years

COVID-19 vaccine containing nucleoside-modified mRNA encoding the spike glycoproteins of SARS-CoV-2 LP.8.1 strain.

Single dose vial without preservative containing 0.3 mL of suspension for injection. Requires no dilution. Each vial contains 1 dose in 0.48mL.

Each 0.3 mL dose contains:

  • 10 µg mRNA encoding the SARS-CoV-2 LP.8.1 spike glycoprotein
  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • Distearoylphosphatidylcholine (DSPC)
  • Cholesterol
  • Trometamol
  • Trometamol hydrochloride
  • Sucrose
  • Water for injections

For Product Information and Consumer Medicine Information about Comirnaty LP.8.1 visit the Therapeutic Goods Administration website.

Additional vaccine information

For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Related diseases
COVID-19

Page history

Last updated
Last reviewed

Help us improve the Australian Immunisation Handbook

Printed content may be out of date. For up to date information, always refer to the digital version:

https://immunisationhandbook.health.gov.au/vaccines/comirnaty-lp81-5-years-to

All vaccines

Link copied

Link, share or bookmark directly to this section of the page.